APGE

Company Overview — What Does Apogee Therapeutics, Inc. Do?

We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Our antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Our two most advanced programs are APG777 and APG808, which we are initially developing for the treatment of AD and COPD, respectively. With our broad pipeline and depth of expertise, we believe we can deliver value and meaningful benefit to patients underserved by today’s standard of care. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. AD is a chronic inflammatory skin disorder that affects approximately 40 million adults and 18 million children in the United States, France, Germany, Italy, Japan, Spain and the United Kingdom, 40% of which have moderate-to-severe disease. Based on our preclinical studies, we believe APG777 can be dosed either every two or every three months in maintenance, which, if our clinical trials are successful, would represent a significant improvement compared to first generation IL-13 antibodies that are dosed every two to four weeks. We have filed for regulatory approval to commence human clinical trials in Australia and we anticipate initiating a Phase 1 clinical trial of APG777 in healthy volunteers in the second half of 2023, subject to regulatory clearance. We expect initial SQ pharmacokinetic (PK) and safety data from this trial in mid-2024. Pending positive data from our Phase 1 trial, we anticipate filing an IND in support of a Phase 2 trial in AD and initiating a Phase 2 trial in AD. Based on our initial clinical data, we may initiate a Phase 2 trial in asthma and expect to further evaluate opportunities to develop APG777 for other I&I indications, including alopecia areata (AA), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), eosinophilic esophagitis (EoE) and prurigo nodularis (PN). APG808 is an SQ extended half-life mAb targeting IL-4Rα. COPD is a heterogenous, progressive respiratory condition characterized by cough, dyspnea and airflow obstruction that affects approximately 32 million adults 40 years of age and older in the United States, France, Germany, Italy, Japan, Spain and the United Kingdom. Based on our preclinical studies, we believe APG808 can be dosed either every six weeks or every two months in maintenance, which, if our clinical trials are successful, would represent a significant improvement compared to first generation IL-4Rα antibodies that are dosed every two weeks. We expect to nominate a development candidate for our APG808 program for the treatment of COPD in 2023, and thereafter intend to file an IND or foreign equivalent prior to the initiation of any clinical trials. Our earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, respectively, which we are initially developing for the treatment of AD. OX40L occurs higher up, or more upstream, in the inflammatory pathway than IL-13 or IL-4Rα and potentially broadens the impact on the inflammatory cascade. With current approved biologics only targeting two mechanisms of action (IL-13 and IL4Rα) in AD, OX40L could represent another therapeutic option for patients, especially the portion of patients who do not benefit from currently available treatments. We expect to nominate a development candidate for APG990 in 2024. In addition, we believe that blocking multiple targets, such as simultaneous inhibition of IL-13 and OX40L in APG222, could allow us to provide benefit to patients with AD and other I&I indications. We believe that each of our programs has the potential to impact multiple additional I&I indications. Apogee Therapeutics, Inc. was incorporated under the laws of the State of Delaware on June 9, 2023. It had no business operations prior to this offering. We are a fully remote company and do not maintain physical corporate offices. Our employees work remotely from home. We maintain a mailing address at 221 Crescent St., Building 17, Suite 102b, Waltham, MA. Apogee Therapeutics, Inc. (APGE) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Michael Henderson. With a market capitalization of $6.3B, APGE is one of the notable companies in the Healthcare sector.

Apogee Therapeutics, Inc. (APGE) Stock Rating — Hold (April 2026)

As of April 2026, Apogee Therapeutics, Inc. receives a Hold rating with a composite score of 36.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.APGE ranks #1,711 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Apogee Therapeutics, Inc. ranks #168 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

APGE Stock Price and 52-Week Range

Apogee Therapeutics, Inc. (APGE) currently trades at $86.00. The stock lost $0.52 (0.6%) in the most recent trading session. The 52-week high for APGE is $84.56, which means the stock is currently trading 1.7% from its annual peak. The 52-week low is $26.20, putting the stock 228.2% above its annual trough. Recent trading volume was 397K shares, suggesting relatively thin trading activity.

Is APGE Overvalued or Undervalued? — Valuation Analysis

Apogee Therapeutics, Inc. (APGE) carries a value factor score of 28/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 6.87x, versus the sector average of 2.75x.

At current multiples, Apogee Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Apogee Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Apogee Therapeutics, Inc. (APGE) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -26.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -25.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

APGE Debt, Balance Sheet, and Financial Health

Apogee Therapeutics, Inc. has a debt-to-equity ratio of 4.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 26.57x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $108M.

APGE has a beta of 1.31, meaning it is more volatile than the broader market — a $10,000 investment in APGE would be expected to move 31.2% more than the S&P 500 on any given day. The stability factor score for Apogee Therapeutics, Inc. is 37/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Apogee Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Apogee Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-4.22. Net income for the quarter was $-235M. Operating income came in at $-266M.

In FY 2025, Apogee Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-4.22. Net income for the quarter was $-256M. Operating income came in at $-286M.

In Q3 2025, Apogee Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.11. Net income for the quarter was $-65M. Operating income came in at $-71M.

In Q2 2025, Apogee Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.13. Net income for the quarter was $-66M. Operating income came in at $-73M.

Over the past 8 quarters, Apogee Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing APGE stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

APGE Dividend Yield and Income Analysis

Apogee Therapeutics, Inc. (APGE) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

APGE Momentum and Technical Analysis Profile

Apogee Therapeutics, Inc. (APGE) has a momentum factor score of 69/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 3/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

APGE vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Apogee Therapeutics, Inc. (APGE) ranks #168 out of 838 stocks based on the Blank Capital composite score. This places APGE in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing APGE against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full APGE vs S&P 500 (SPY) comparison to assess how Apogee Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

APGE Next Earnings Date

No upcoming earnings date has been announced for Apogee Therapeutics, Inc. (APGE) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy APGE? — Investment Thesis Summary

Apogee Therapeutics, Inc. presents a balanced picture with arguments on both sides. The quality score of 28/100 flags below-average profitability. The value score of 28/100 indicates premium valuation. Price momentum is positive at 69/100, suggesting the trend favors buyers. High volatility (stability score 37/100) increases portfolio risk.

In summary, Apogee Therapeutics, Inc. (APGE) earns a Hold rating with a composite score of 36.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on APGE stock.

Related Resources for APGE Investors

Explore more research and tools: APGE vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare APGE head-to-head with peers: APGE vs AZN, APGE vs SLGL, APGE vs VMD.